Fibrosis in chronic liver diseases: diagnosis and management

被引:188
作者
Pinzani, M
Rombouts, K
Colagrande, S
机构
[1] Univ Florence, Ctr Ric Trasferimento & Alta Formaz, DENOTHE, Dipartimento Med Interna, I-50134 Florence, Italy
[2] Univ Florence, Dipartimento Fisiopatol Clin, Unita Radiol, Florence, Italy
关键词
D O I
10.1016/j.jhep.2004.12.008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Progressive hepatic fibrosis is the common consequence of most chronic liver diseases. Following the elucidation of the cellular and molecular mechanisms responsible for this process, increasing interest concerning the possible translation" of these advancements into clinical applications has developed in recent years. This also in view of the still theoretical possibility of treating hepatic fibrosis with pharmacological agents. Current relevant issues are: (1) the need of an accurate and effective monitoring of the fibrotic progression of chronic liver diseases and of the effectiveness of the currently proposed treatments; (2) the identification of general or individual factors potentially relevant for a faster progression of the disease; (3) the need of starting clinical trials aimed to test antifibrogenic drugs with clear end-points. © 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved."
引用
收藏
页码:S22 / S36
页数:15
相关论文
共 157 条
[51]  
Guechot J, 1996, CLIN CHEM, V42, P558
[52]  
Guido M, 2004, SEMIN LIVER DIS, V24, P89
[53]   Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture [J].
Gutiérrez-Ruiz, MC ;
Bucio, L ;
Correa, A ;
Souza, V ;
Hernández, E ;
Gómez-Quiroz, LE ;
Kershenobich, D .
PHARMACOLOGICAL RESEARCH, 2001, 44 (05) :431-436
[54]   SERUM CONCENTRATIONS OF THE CARBOXYTERMINAL CROSS-LINKING DOMAIN OF PROCOLLAGEN TYPE-IV (NC1) AND THE AMINOTERMINAL PROPETIDE OF PROCOLLAGEN TYPE-III (PIIIP) IN CHRONIC LIVER-DISEASE [J].
HAYASAKA, A ;
SCHUPPAN, D ;
OHNISHI, K ;
OKUDA, K ;
HAHN, EG .
JOURNAL OF HEPATOLOGY, 1990, 10 (01) :17-22
[55]   Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids [J].
Hellemams, K ;
Verbuyst, P ;
Quartier, E ;
Schuit, F ;
Rombouts, K ;
Chandraratna, RAS ;
Schuppan, D ;
Geerts, A .
HEPATOLOGY, 2004, 39 (01) :97-108
[56]   All-trans and 9-cis retinoic acid alter rat hepatic stellate cell phenotype differentially [J].
Hellemans, K ;
Grinko, I ;
Rombouts, K ;
Schuppan, D ;
Geerts, A .
GUT, 1999, 45 (01) :134-142
[57]   Three-dimensional reconstruction of hepatic bridging fibrosis in chronic hepatitis C viral infection [J].
Hoofring, A ;
Boitnott, J ;
Torbenson, M .
JOURNAL OF HEPATOLOGY, 2003, 39 (05) :738-741
[58]  
Huang Z, 2000, Zhongguo Zhong Xi Yi Jie He Za Zhi, V20, P447
[59]   Prostaglandin E2 inhibits transforming growth factor β1-mediated induction of collagen α1(I) in hepatic stellate cells [J].
Hui, AY ;
Dannenberg, AJ ;
Sung, JJY ;
Subbaramaiah, K ;
Du, BH ;
Olinga, P ;
Friedman, SL .
JOURNAL OF HEPATOLOGY, 2004, 41 (02) :251-258
[60]   Activated rat stellate cells express c-met and respond to hepatocyte growth factor to enhance transforming growth factor β1 expression and DNA synthesis [J].
Ikeda, H ;
Nagoshi, S ;
Ohno, A ;
Yanase, M ;
Maekawa, H ;
Fujiwara, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (03) :769-775